Stock Price Quote

ORTIN LABORATORIES LTD.

NSE : ORTINLABBSE : 539287ISIN CODE : INE749B01020Industry : Pharmaceuticals & DrugsHouse : Private
BSE20.03-1.82 (-8.33 %)
PREV CLOSE ( ) 21.85
OPEN PRICE ( ) 21.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 21544
TODAY'S LOW / HIGH ( )19.67 21.80
52 WK LOW / HIGH ( )16.15 30.33
NSE19.95-1.8 (-8.28 %)
PREV CLOSE( ) 21.75
OPEN PRICE ( ) 21.25
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 19.95 (4157)
VOLUME 126256
TODAY'S LOW / HIGH( ) 19.60 21.25
52 WK LOW / HIGH ( )16.2 30.35
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 27-10 1986
Management Info
Murali Krishna Rayaprolu - Chairman S Murali Krishna Murthy - Managing Director
Registered Office

Address D No.1-8- B 4, Ground Floor,F3 H I G, Block - 4, Street No.3,Baghlingampally,
Hyderabad,
Telangana-500044

Phone 040-27567266 / 27562055

Email info@ortinlabsindia.com

Website www.ortinlabsindia.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Chennai

NEWS

08Apr Clarification On Price Movement
Clarification on Price Movement with reference to BSE Email dated 05-04-..
02Apr Ortin Laboratories informs about discl
Ortin Laboratories has informed that the exchange has received the discl..
14Dec Ortin Laboratories informs about outco
Ortin Laboratories has informed that the 1% Extraordinary General Meetin..
16Nov Ortin Laboratories informs about newsp
With reference to the Regulation 47(1)(b) read with Schedule III of SEBI..
10Jun Ortin Laboratories submits disclosure
Ortin Laboratories has submitted the disclosure underRegulation 29(2) of..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit-27.92-0.660000000000004
Gross Profit -28.08 -0.830000000000005
Operating Profit -26.035.63
Net Sales 1.3760.2

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  6660.85 (7.79%)
M.Cap ( in Cr)8545.80
Concord Biotech (BSE)
peergroup  1561.65 (3.68%)
M.Cap ( in Cr)16337.39
Sanofi India (BSE)
peergroup  8490.90 (0.51%)
M.Cap ( in Cr)19555.07
JB Chem & Pharma (BSE)
peergroup  1800.50 (2.37%)
M.Cap ( in Cr)27942.82
Divi's Lab (BSE)
peergroup  3779.20 (1.08%)
M.Cap ( in Cr)100325.89

Shareholding Pattern

NON-INSTITUTION 92.64%
PROMOTERS 7.36%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Ortin Laboratories Ltd.

Ortin Laboratories Ltd. was incorporated in the year 1986. Its today's share price is 20.03. Its current market capitalisation stands at Rs 16.29 Cr. In the latest quarter, company has reported Gross Sales of Rs. 60.2 Cr and Total Income of Rs.60.62 Cr. The company's management includes Shashikant Shankarrao Igave, Pramod Dnyandeo Waghe, Divya Purswani, S Srinivas Kumar, Pottur Sujatha, B Gopal Reddy, S Balaji Venkateswarlu, S Murali Krishna Murthy, Murali Krishna Rayaprolu.

It is listed on the BSE with a BSE Code of 539287 , NSE with an NSE Symbol of ORTINLAB and ISIN of INE749B01020. It's Registered office is at D No.1-8- B 4, Ground Floor,F3 H I G, Block - 4, Street No.3,BaghlingampallyHyderabad-500044, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Mathesh & Ramana, Sathuluri & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.